Biomolecules· 2026Q1· Review
Lifestyle-Associated Biomarkers of Cellular and Whole-Organism Aging: A Practical Roadmap for Human Geroscience Trials
- 0citations
- Q1SCImago
- 2026year
Short summary
This review proposes a practical, mechanism-based framework and study-design roadmap for geroscience trials, integrating multiple biomarker domains to assess lifestyle intervention effects on human aging.
AI-generated from the title and abstract; the full text is not read.
Key points
- Proposes a mechanism-based framework for studying lifestyle effects on human aging.
- Reviews major biomarker domains including epigenetic clocks, senescence, inflammaging, and metabolic pathways.
- Discusses criteria for biomarker selection in geroscience trials (biological relevance, validity, responsiveness, feasibility, reproducibility, interpretability).
- Outlines a practical study-design roadmap for biospecimen collection, assessments, and endpoint integration.
AI-generated from the title and abstract; the full text is not read.
Abstract
Aging is a multidimensional biological process that is not adequately captured by chronological age alone. Geroscience—the study of biological mechanisms that drive age-related functional decline and disease susceptibility—therefore requires biomarker frameworks that can identify biological aging trajectories and assess whether lifestyle-associated interventions meaningfully influence aging-related pathways. In this review, we propose a practical, mechanism-based framework for studying lifestyle-associated effects on cellular and whole-organism aging in humans. We examine major biomarker domains, including DNA-methylation-based epigenetic aging clocks, cellular senescence-associated measures, senescence-associated secretory phenotype factors, inflammaging mediators, oxidative stress indicators, mitochondrial function, metabolic and nutrient-sensing pathways, proteomic and metabolomic signatures, microbiome-associated markers, and functional measures of frailty, mobility, cognition, and resilience. We also discuss criteria for biomarker selection in exploratory and multicenter trials, emphasizing biological relevance, analytical validity, responsiveness to intervention, feasibility, reproducibility, and clinical interpretability. Finally, we outline a practical study-design roadmap integrating biospecimen collection, repeated assessments, core and exploratory biomarker panels, and functional endpoints. A biomarker-guided geroscience strategy may provide a practical route for connecting mechanistic aging biology with clinically relevant human studies designed to preserve healthspan and functional independence.
The authors' abstract, as published at the source. Biomolecules, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
AgingBiochemistry, Genetics and Molecular Biology